Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Archives of Pediatrics and Adolescent Medicine, 161(11): 1-9, 2007.
Mikulich-Gilbertson SK, Salomonsen-Sautel S, Sakai, JT, Booth RE. Gender similarities and differences in antisocial behavioral syndromes among injection drug users. American Journal on Addictions, 16, 372-382 , 2007.
Hopfer CJ, Lessem JM, Hartman CA, Stallings MC, Cherny SS, Corley RP, Hewitt JK, Krauter KS, Mikulich-Gilbertson SK, Rhee SH, Smolen A, Young SE, Crowley TJ. A genome-wide scan for loci influencing adolescent cannabis dependence symptoms: Evidence for linkage on chromosomes 3 and 9. Drug and Alcohol Dependence, 89(1), 34-41, 2007.
Sakai JT, Mikulich-Gilbertson SK, Long RJ, Crowley TJ. Validity of transdermal alcohol monitoring: fixed and self-regulated dosing. Alcoholism: Clinical and Experimental Research, 30(1), 26-33, 2006.
Crowley TJ, Raymond KE, Mikulich-Gilbertson SK, Thompson LL, Lejuez CW. A risk- taking “set” in a novel task among adolescents with serious conduct and substance problems. J Am Acad Child Adolesc Psychiatry, 45(2): 175-183, 2006.
Carroll KM, Ball SA, Nich C, Martino S, Frankforter TL, Farentinos C, Kunkel LE, Mikulich-Gilbertson SK, Morgenstern J, Obert JL, Polcin D, Snead N, Woody GE. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: A multisite effectiveness study. Drug and Alcohol Dependence, 81(3):301-312, 2006.
Swenson CJ, Marshall J, Mikulich-Gilbertson SK, Baxter J, Morgenstern N. Physical Activity in Older, Rural, Hispanic, and Non-Hispanic White Adults. Medicine and Science in Sports and Exercise: 995-1002, 2005.
Booth RE, Mikulich-Gilbertson SK, Brewster JT, Salomonsen-Sautel S, Semerik O. Predictors of Self-Reported HIV Infection Among Drug Injectors in Ukraine. Journal of Acquired Immune Deficiency Syndrome, 35, 82-88, 2004.
Mikulich SK, Zerbe GO, Jones RH, Crowley TJ. Comparing linear and nonlinear mixed model approaches to cosinor analysis. Statistics in Medicine, 22(20), 3195-3211, 2003.
Mikulich SK, Hall SK, Whitmore EA, Crowley TJ. Concordance between DSM-III-R and DSM-IV diagnoses of substance use disorders in adolescents. Drug Alcohol Depend, 61(3), 237-248, 2001.
Mikulich SK, Zerbe GO, Jones RH, Crowley TJ. Relating the classical covariance adjustment techniques of multivariate growth curve models to modern univariate mixed effects models. Biometrics, 55, 957-964, 1999.
Title: Substance Dependent Adolescents: Imaging Risk-Taking
The objective of this research is to better understand whether substances diminish the capacity to inhibit behavior by altering brain processing of risky decisions, or do pre-existing, anatomically-based variations of brain processing produce risk-taking propensities, or both.
Role: Co-Investigator and Statistician
2 R01 DA009842-13
NIH/NIDA
Dates: 09/05/2006 - 04/30/2011
Title: Martial Arts As Early Intervention for Teen Drug Abuse
This is a Stage 1A/1B behavioral therapies development grant with the primary aims of developing a manualized early intervention for adolescent substance abuse (based on traditional martial arts) and then conducting a pilot study in order to estimate the effect size of the intervention and provide information for estimating power for a larger randomized controlled trial.
Role: Co-Investigator, Statistician
1R01 DA018679-03 (Davies)
NIH/NIDA
Dates:
05/01/2006 - 04/30/2009
Title: The Increasing Disparity In Illegal Drug Use Across Socioeconomic Strata
This project focuses on the increasing disparity in illegal drug use/dependence across socioeconomic strata in recent decades, seeking first to document socioeconomic trends in drugs other than cocaine and update socioeconomic trends in illegal drug use past 1998. Second, the project will evaluate changes in the prevalence of illegal drugs over time and also changes in the characteristics of illegal drug users over time using a "Diffusion of Innovation" framework. Finally, the project will trace the extent to which the key predictors of illegal drug use have their roots in the early life course.
Role: Co-Investigator and Statistician
1 R01 DA020575-02 (Miech)
NIH/NIDA
Dates:
07/01/2007 - 06/31/2010
Title: Synergy Assertive Continuing Care: Using ACC/ACRA as an Aftercare Model
This federally-funded grant will provide aftercare services utilizing the ACC/ACRA model to 144 substance-abusing youth leaving either residential or day treatment.
Role: Biostatistician
5H79 TI017648-02 (Whitmore)
DHSS/SAMSHA/CSAT
Dates: 09/30/2007-09/29/2010
Title: Genetics of Adolescent Antisocial Drug Dependence (COMRAD)
This COMRAD proposal continues a multi-site collaboration, initiated under DA012845, to conduct a prospective study to address critical issues in the genetic epidemiology of adolescent onset antisocial drug dependence. We will complete five year follow-up assessments, examine drug use and antisocial behavior trajectories and their predictors, and we will conduct genome wide association analyses of persistent adolescent-onset antisocial drug dependence.
Role: Co-Investigator, Statistician
5R01 DA021913-02 (Hopfer)
NIH/NIDA
Dates: 07/01/2008-12/31/2012
Title: Clinical Trials Network, Ohio Valley Node
Dr. Riggs', UCD PI, involvement with the Clinical Trials Network continues via a subaward arrangement with the University of Cincinnati/ Ohio Valley Node. The protocol: "A Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder in Adolescents with Substance Use Disorders" (CTN-0028), the conduct of which is supported under this subaward.
Role: Biostatistician
U10 DA013732-09 (Somoza)
NIH/NIDA (UCD Subcontract)
Dates: 09/30/2000-08/31/2010
Title: Psychoeducation for BMT Caregivers: Biobehavioral Markers and Outcome
This randomized controlled trial will test the efficacy of a psychoeducational intervention for caregivers of patients undergoing bone marrow transplant. Outcome measures will include psychosocial and biological outcomes (e.g., immune and neuroendocrine)
Role: Co-Investigator, Statistician
1R01 CA126971-01A1 (Laudenslager)
NIH/NCI
Dates: 06/01/2008-04/30/2013
Title: Bupropion for ADHD in Adolescents with Substance Use Disorders
The primary aims of this study are: 1) To assess the safety and efficacy of bupropion versus placebo in treating ADHD in adolescents with SUD; 2) To assess the safety and efficacy of bupropion versus placebo in reducing nicotine use in adolescents with ADHD and SUD. Secondary Aims: 3) To evaluate the impact of bupropion versus placebo on non-nicotine drug use (including cannabis); 4) To evaluate the impact of bupropion versus placebo on depressive symptoms in the subsample who meet DSM-IV criteria for major depressive disorder (MDD).
Role: Co-Investigator, Statistician
1R01 DA022284-01A1 (Riggs)
NIH/NIDA
Dates: 08/15/2008-06/30/2013
Title: Antisocial Drug Dependence: Genetics
Core B: Informatics Core
Center representing the University of Colorado’s Division of Substance Dependence, Institute for Behavioral Genetics, and Molecular, Cellular, and Developmental Biology. This center conducts research in antisocial drug dependence and human behavioral genetics.
Role: Co-Principal Investigator and Statistician
2 P60 DA 011015-07
NIH/NIDA
Dates: 08/15/2003 - 04/30/2008
Title: Subcontract for HIV/HCV in Drug Treatment Settings (CTN-0017)
The objective of this subcontract with the EMMES Corporation is to complete the protocol "HIV/HCV in Drug Treatment Settings" (CTN-0017) by supporting two local community treatment programs (CTPs) conducting the study and the continuity of infrastructure provided by the Lead Investigator team required for completion of the study and direction of the two CTPs.
Role: Statistician
HHSN271200522081C
NIH/NIDA
Dates: 09/01/2005 - 08/31/2007
Title: Rocky Mountain Regional Clinical Trials Node
Conduct studies of behavioral, pharmacological, and integrated behavioral and pharmacological treatment inventions of therapeutic effect in rigorous, multi-site clinical trials to determine effectiveness across a broad range of community-based treatment settings and diversified patient populations.
Role: Co-Investigator and Statistician
5 U10 DA13716-05
NIH/NIDA
Dates: 09/30/2000 - 08/31/2005
Title: Genetics of Adolescent Antisocial Drug Dependence
The major goal (NIDA RFA DA-99-003) is to conduct a multi-site whole-genome search for chromosomal loci influencing early-onset antisocial drug dependence. Ascertainment, assessment, and collection of blood from probands and family members will be conducted through clinical research programs in two cities (Denver and San Diego). Data analyses and molecular studies at University of Colorado, Boulder.
Role: Statistician
5 R01 DA 012845-04
NIH/NIDA
Dates: 09/15/2000 - 02/28/2006
Title: Substance Dependent Teens: Impact of Treating Depression
This clinical trial assesses the impact of fluoxetine as compared to placebo in adolescents receiving treatment for comorbid depression, conduct disorder, and substance use disorders.
Role: Co-Investigator and Statistician
5R01 DA13176-05
NIH/NIDA
Dates:
09/30/2000 - 07/31/2007
Mentoring:
Individual mentoring (by assisting with research projects, assisting with writing grants, and serving and/or chairing thesis and dissertation committees, etc.) of medical students, psychiatric residents, and graduate students in biostatistics, epidemiology, and public health.
